Company profile
Lite Strategy, Inc.
NASDAQ: LITS · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
49DFH 51DQ 63GM 17SS 49
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$15.9M
Employees
4
as of 2026-08-20
Market cap
$32.0M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$15.9M-$15.9M2025
Operating income-$17.5M-$17.5M2025
Total assets$18.3M$18.3M2025
Liabilities$1.4M$1.4M2025
Equity$16.9M$16.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lite Strategy, Inc.’s revenue?
Lite Strategy, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Noveris Health Sciences Inc.——Grace Therapeutics, Inc.48DNanoViricides, Inc.35DHigh Sierra Technologies, Inc.——BeyondSpring Inc.34DSona Nanotech Inc.——Neighbors
San Diego →Key facts
CEOJustin J. File
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: LITS
Employees4
IPO date2003-12-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.